Pembrolizumab Activity in Recurrent High-Grade Gliomas with Partial or Complete Loss of Mismatch Repair Protein Expression: A Monocentric, Observational and Prospective Pilot Study.
Giuseppe LombardiValeria BarresiStefano IndraccoloMichele SimboloAngelo Paolo Dei TosSusanna MandruzzatoMatteo SimonelliMario CacceseMarco PizziArianna FassinaMarta PadovanElena MasettoMarina Paola GardimanMaria Giuseppina BonavinaMaria CaffoPasquale PersicoFranco ChioffiLuca DenaroAngelo Paolo Dei TosAldo ScarpaVittorina ZagonelPublished in: Cancers (2020)
pembrolizumab showed no apparent benefit in these patients. No molecular biomarker was found to be associated with pembrolizumab activity.